Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Herbst, RS; Giaccone, G; de, Marinis; Reinmuth, N; Vergnenegre, A; Barrios, CH; Morise, M; Felip, E; Andric, Z; Geater, S; Özgüroğlu, MUSTAFA; Zou, W; Sandler, A; Enquist, I; Komatsubara, K; Deng, Y; Kuriki, H; Wen, X; McCleland, M; Mocci, S; Jassem, J; Spigel, DR

doi:10.1056/nejmoa1917346

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

Herbst R., Giaccone G., de M., Reinmuth N., Vergnenegre A., Barrios C., ...Daha Fazla

The New England journal of medicine, cilt.383, ss.1328-1339, 2020 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 383
Basım Tarihi: 2020
Doi Numarası: 10.1056/nejmoa1917346
Dergi Adı: The New England journal of medicine
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
Sayfa Sayıları: ss.1328-1339
İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır

Özet

BackgroundThe efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) with PD-L1 expression are not known.